<DOC>
	<DOCNO>NCT00588991</DOCNO>
	<brief_summary>This phase I trial study side effect best dose veliparib give together topotecan hydrochloride without carboplatin treat patient relapsed refractory acute leukemia , high-risk myelodysplasia , aggressive myeloproliferative disorder . Veliparib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , topotecan hydrochloride carboplatin , work different way stop growth cancer cell , either kill cell stop divide . Giving veliparib together topotecan hydrochloride carboplatin may kill cancer cell .</brief_summary>
	<brief_title>Veliparib Topotecan With Without Carboplatin Treating Patients With Relapsed Refractory Acute Leukemia , High-Risk Myelodysplasia , Aggressive Myeloproliferative Disorders</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine feasibility , tolerability , toxicity ABT-888 ( veliparib ) administer alone combination topotecan hydrochloride without carboplatin patient relapse refractory acute leukemia , high-risk myelodysplasia , aggressive myeloproliferative disorder . II . To determine maximum tolerate dose ABT-888 administer topotecan hydrochloride carboplatin patient . III . To determine ABT-888 administered topotecan hydrochloride carboplatin induce clinical response patient . SECONDARY OBJECTIVES : I . To determine pharmacokinetics ABT-888 administer alone combination topotecan hydrochloride without carboplatin patient . II . To obtain pharmacodynamic data regard ability ABT-888 inhibit poly ( ADP-ribose ) level leukemic blast . III . To obtain descriptive data regard mutational status and/or methylation status key gene select DNA repair pathway ( Fanconi complementation group A-F , Blooms , ataxia-telangiectasia ) leukemic blast . OUTLINE : This multicenter , dose-escalation study veliparib . Patients receive veliparib orally twice daily day 1-8 , 1-14 , 1-21 topotecan hydrochloride without carboplatin IV continuously 120 hour day 3-7 . Treatment repeat every 28-63 day 6 course absence disease progression unacceptable toxicity . Patients undergo blood sample collection periodically pharmacokinetic study . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Pathologically confirm diagnosis 1 aggressive MPD AML MPD Aggressive phase highrisk myeloproliferative disorder ( i.e. , polycythemia vera , essential thrombocythemia , Phnegative chronic myelogenous leukemia ) meeting â‰¥ 1 follow criterion : Marrow blast &gt; 5 % Peripheral blood blast plus progranulocytes &gt; 10 % New onset increase myelofibrosis OR ; New onset &gt; 25 % increase hepatomegaly splenomegaly New onset constitutional symptom ( i.e. , fever , weight loss , splenic pain , bone pain ) Patients fail primary induction therapy relapse achieve complete remission eligible No active CNS leukemia ; patient history CNS disease must stable &gt; 3 month treatment steroid treatment prior study enrollment Chronic myelomonocytic leukemia meeting either follow criterion : 519 % bone marrow blast ( aggressive ) At least 20 % marrow blast ( transformation ) ECOG performance status 02 No hyperleukocytosis &gt; = 50,000 blasts/uL AST , ALT , alkaline phosphatase = &lt; 5 time upper limit normal Bilirubin = &lt; 2.0 mg/dL Creatinine normal OR creatinine clearance &gt; = 60 mL/min LVEF &gt; = 45 % MUGA ECHO Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day completion study therapy No active disseminate intravascular coagulation No active uncontrolled infection Patients infection active treatment control antibiotic eligible No lifethreatening illness No mental deficit and/or psychiatric history would preclude give informed consent follow protocol No prior current seizure disorder history seizure No 3 prior cytotoxic regimen At least 3 week since prior cytotoxic chemotherapy At least 2 week since prior radiotherapy At least 4 week since prior autologous allogeneic stem cell transplantation No active graftversushost disease At least 1 week since prior biologic therapy , include hematopoietic growth factor At least 24 hour since prior hydroxyurea , steroid , imatinib mesylate , arsenic trioxide , interferon , noncytotoxic agent blast count control No prior ABT888 No concurrent chemotherapy , radiotherapy , immunotherapy No concurrent antiretroviral therapy HIVpositive patient No concurrent investigational commercial agent therapy cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>